I agree with Surges on today's half yearly jarrody,
What we can expect to see under the review of Operations, as Surges has mentioned, is a non-material update on the commercial activities undertaken by the company up until the end of the December reporting period, ie JDA negotiations are progressing as anticipated, our Dermaportation patent being granted in the US has attracted further commercial opportunities and discussions with various International groups are progressing well etc etc etc - don't expect to see anything of a sensitive nature but hopefully we'll get a confident message shining through the words
Our internal development program re the musculoskeletal pain eM-patch might also get a mention providing us with additional non-sensitive news.
Expansion with staffing, lab tech, academic collaboration should also be reported on.
If they continue down this more recently prevelent under-the-radar approach we might not expect to see today's report until after session close.
Here's a couple of bits and bobs to distract you for a couple of minutes while we await our Perth cousins to rise and shine this morning:
Did you know...
1) The highest closing price since OBJ's inception in 2004: Recorded on 20/01/2006 when it closed @ 0.094c on no announcement. ___
2) The highest closing price within the last 5 years:
$0.064c recorded on 16/03/2010 when OBJ announced the appointment of former partner and licensing expert of 30 years with Reckitt Benckiser, Unilever, PZ Cussons, CB Fleet and GSK - Dr Kevin Hammond joined OBJ to Head the International Partnering efforts. ___
3) Top 10 Volume traded days:
26/10/2010: 391961043 - GSK to Progress FIM Technology 05/11/2009: 319593124 - OBJ Enters into MTA with 3M 19/02/2010: 292853493 - GSK enters into further agreement (18/02) 18/02/2010: 268895225 - GSK enters into further agreement 27/10/2009: 256900019 - No Announcement 26/10/2009: 214367405 - No announcement 25/01/2010: 206217341 - No Announcement (Extension to MTA 28/01) 17/03/2010: 205560823 - Response to ASX Query 08/02/2010: 204512276 - FMCG Statement of Intent ___
4) The fasted short term percentage rise was + 1500.00% in 5.5 months from September 2009 to March 2010 when the ASX, as some have alleged, were prompted by a "shareholder" to stop the momentum.
* 17/12/2009 - * Pharmaceutical Journal Publication: The Dermaportation technology (OBJ Limited) used in the experiments published in December 2009 generated an asymmetrical pulse packet type electromagnetic field comprised of a series of repeating quasi-rectagular waves of electromagnetic energy with peak maximum field strength of 5mT. The electromagnetic pulse is propagated through the energizing of a small spirally wound monofilament air-filled coil which is placed externally to the donor compartment of the Franz type diffusion cell so that the energising coil was 7mm above the skin surface. The PEMF system utilizes a secure microprocessor smart card technology with automatic CRC data integrity testing and systems integrity testing to ensure the quality and repeatability of the field characteristics between experiments.
The aim of this study was to evaluate the skin permeation of naltrexone under the influence of pulsed electromagnetic fields (PEMF). ___
5 facts you should know about Dermaportation
* The amount of energy required to carry out this transdermal delivery technique is approximately 1000 times less than the corresponding energy levels required for iontophoresis and electroporation transdermal delivery techniques. As a consequence, it is ideally suited to implementation in compact, portable and disposable applications, in particular for outpatient and homecare use.
* Since the technique is inductive, it can operate through most non-conductive materials such as bandages without the requirement for physical contact with the skin.
* This technique can not be sensed or felt by humans and, as a result, is painless and has none of the undesirable side effects commonly associated with techniques such as iontophoresis and electroporation.
* The control circuitry, for example a microcontroller, may be configured so that the apparatus carries out a specific treatment plan, for example by generating an appropriate energisation signal pattern and using the energisation signal to apply one or more specific electromagnetic field patterns to a target area of a patient at specific times of for a specific time duration.
* The therapeutic substance may be a drug, vaccine, ion, macromolecule, DNA fragment, gene or any other substance desired to be passed through the skin of a patient for the purpose of obtaining a beneficial effect.
OBJ Price at posting:
1.9¢ Sentiment: LT Buy Disclosure: Held
(20min delay)